 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...121122123124125126127128129130131132133» |
- | everolimus / Generic mfg., exemestane / Generic mfg.
Trial completion, Combination therapy, Metastases: An expanded access study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who have progressed following prior endocrine therapy, investigating the treatment of everolimus (RAD001) in combination with exemestane (EUDRACT) - Apr 19, 2013
P3, N=2200, Completed, Sponsor: Novartis Pharma Services AG`NOVARTIS FARMACEUTICA S.A`NOVARTIS FARMA
Ongoing --> Completed
- |||| Farydak (panobinostat) / Secura Bio
Enrollment open: Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Apr 14, 2013
P2, N=75, Recruiting, Sponsor: Anne Beaven
Ongoing --> Completed Active, not recruiting --> Recruiting
- || Trial initiation date, Gene Expression Profile, IO biomarker, Biopsy, Post-transplantation: Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens (clinicaltrials.gov) - Apr 10, 2013
P=N/A, N=80, Recruiting, Sponsor: Northwestern University
Active, not recruiting --> Recruiting Initiation date: Jul 2012 --> Feb 2013
- ||| Enrollment open, Gene Expression Profile, IO biomarker, Biopsy, Post-transplantation: Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens (clinicaltrials.gov) - Apr 10, 2013
P=N/A, N=80, Recruiting, Sponsor: Northwestern University
Initiation date: Jul 2012 --> Feb 2013 Not yet recruiting --> Recruiting
- everolimus / Generic mfg.
Trial completion, Metastases: RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Apr 10, 2013
P2, N=49, Completed, Sponsor: Seoul National University Hospital
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | everolimus / Generic mfg.
New P2 trial, Metastases: RAD001 in Advanced Sarcoma (clinicaltrials.gov) - Apr 10, 2013
P2, N=41, Completed, Sponsor: Asan Medical Center
- everolimus / Generic mfg., sorafenib / Generic mfg.
Trial termination, Metastases: Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Apr 8, 2013
P1, N=130, Terminated, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Completed --> Terminated
- | veliparib (ABT-888) / AbbVie, Mekinist (trametinib) / Novartis, BeiGene, adavosertib (AZD1775) / AstraZeneca
New P2 trial, PARP Biomarker, Metastases: MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations (clinicaltrials.gov) - Apr 7, 2013
P2, N=700, Recruiting, Sponsor: National Cancer Institute (NCI)
- ||||| everolimus / Generic mfg., mycophenolate mofetil / Generic mfg.
Trial initiation date: Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients (clinicaltrials.gov) - Apr 3, 2013
P3, N=106, Recruiting, Sponsor: Novartis Pharmaceuticals
Completed --> Terminated Initiation date: Mar 2012 --> Aug 2012
- everolimus / Generic mfg., docetaxel / Generic mfg.
New P2 trial, P2 data, Metastases: Phase II: RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Apr 3, 2013
P2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
- Sutent (sunitinib) / Pfizer
Trial withdrawal, Metastases: Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Apr 3, 2013
P2, N=0, Withdrawn, Sponsor: Andrea Harzstark
Initiation date: Mar 2012 --> Aug 2012 Not yet recruiting --> Withdrawn
- Sutent (sunitinib) / Pfizer
Enrollment change, Metastases: Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Apr 3, 2013
P2, N=0, Withdrawn, Sponsor: Andrea Harzstark
Not yet recruiting --> Withdrawn N=49 --> 0
- ||||| Enrollment change: RAD: Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients (clinicaltrials.gov) - Apr 1, 2013
P3, N=719, Completed, Sponsor: Novartis Pharmaceuticals
N=49 --> 0 N=1378 --> 719
- everolimus / Generic mfg., sorafenib / Generic mfg.
Enrollment closed: Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer (clinicaltrials.gov) - Apr 1, 2013
P2, N=41, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
N=1378 --> 719 Recruiting --> Active, not recruiting
- | everolimus / Generic mfg.
Enrollment open: Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex (clinicaltrials.gov) - Mar 24, 2013
P2/3, N=60, Recruiting, Sponsor: Erasmus Medical Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- everolimus / Generic mfg.
Trial initiation date: Study of Everolimus in de Novo Renal Transplant Recipients (clinicaltrials.gov) - Mar 13, 2013
P=N/A, N=1, Terminated, Sponsor: Helady Pinheiro, MD, PhD
Not yet recruiting --> Recruiting Initiation date: Jun 2012 --> Mar 2013
- everolimus / Generic mfg., sorafenib / Generic mfg.
Enrollment closed, Combination therapy, Metastases: SAKK 77/08: Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer (clinicaltrials.gov) - Mar 13, 2013
P2, N=106, Active, not recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Initiation date: Jun 2012 --> Mar 2013 Recruiting --> Active, not recruiting
- carboplatin / Generic mfg., everolimus / Generic mfg., paclitaxel / Generic mfg.
Enrollment closed, Surgery, Metastases: CAPRA: Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Mar 11, 2013
P1/2, N=49, Active, not recruiting, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| everolimus / Generic mfg., bicalutamide / Generic mfg.
Enrollment closed, Metastases: Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer (clinicaltrials.gov) - Mar 10, 2013
P2, N=80, Active, not recruiting, Sponsor: University of California, Davis
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- everolimus / Generic mfg., mycophenolate sodium / Generic mfg.
Enrollment open, Biopsy: Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium (clinicaltrials.gov) - Mar 5, 2013
P3, N=50, Recruiting, Sponsor: University of Miami
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || everolimus / Generic mfg.
New P3 trial: UNIRAD: Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy (clinicaltrials.gov) - Mar 4, 2013
P3, N=1984, Recruiting, Sponsor: UNICANCER
- everolimus / Generic mfg., sorafenib / Generic mfg.
New P2 trial: SERIO: Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma (clinicaltrials.gov) - Mar 3, 2013
P2, N=37, Active, not recruiting, Sponsor: Italian Sarcoma Group
- everolimus / Generic mfg., gemcitabine / Generic mfg., sorafenib / Generic mfg.
Trial completion, Metastases: Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride (clinicaltrials.gov) - Feb 27, 2013
P1/2, N=12, Completed, Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || everolimus / Generic mfg.
New P3 trial: AFINIVEST: The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium (clinicaltrials.gov) - Feb 26, 2013
P3, N=53, Recruiting, Sponsor: Hopital Foch
- everolimus / Generic mfg.
Enrollment change, Metastases: Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer (clinicaltrials.gov) - Feb 25, 2013
P2, N=40, Recruiting, Sponsor: Yonsei University
Active, not recruiting --> Completed N=32 --> 40
- lapatinib / Generic mfg., everolimus / Generic mfg.
Trial termination, Combination therapy, Metastases: A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer (clinicaltrials.gov) - Feb 24, 2013
P2, N=5, Terminated, Sponsor: Emory University
N=32 --> 40 Recruiting --> Terminated; Slow accrual, Funding stopped
- lapatinib / Generic mfg., everolimus / Generic mfg.
Enrollment change, Combination therapy, Metastases: A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer (clinicaltrials.gov) - Feb 24, 2013
P2, N=5, Terminated, Sponsor: Emory University
Recruiting --> Terminated; Slow accrual, Funding stopped N=43 --> 5
- | Avastin (bevacizumab) / Roche
Enrollment closed, Metastases: Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy (clinicaltrials.gov) - Feb 24, 2013
P3, N=700, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=43 --> 5 Recruiting --> Active, not recruiting
- | Herceptin (trastuzumab) / Roche
Trial completion, Combination therapy, Metastases: Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer (clinicaltrials.gov) - Feb 21, 2013
P1/2, N=40, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | metformin / Generic mfg., letrozole / Generic mfg., everolimus / Generic mfg.
New P2 trial, Metastases: A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma (clinicaltrials.gov) - Feb 20, 2013
P2, N=64, Recruiting, Sponsor: M.D. Anderson Cancer Center
- ||||| everolimus / Generic mfg., fulvestrant / Generic mfg.
New P2 trial, Metastases: Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI (clinicaltrials.gov) - Feb 20, 2013
P2, N=130, Recruiting, Sponsor: PrECOG, LLC.
- cisplatin / Generic mfg., everolimus / Generic mfg.
Trial termination, Metastases: RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - Feb 19, 2013
P1, N=3, Terminated, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed Not yet recruiting --> Terminated
- cisplatin / Generic mfg., everolimus / Generic mfg.
Enrollment change, Metastases: RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - Feb 19, 2013
P1, N=3, Terminated, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Terminated N=34 --> 3
- | everolimus / Generic mfg.
Enrollment closed, Monotherapy, Surgery: NFitor: Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas (clinicaltrials.gov) - Feb 18, 2013
P2, N=32, Active, not recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
N=34 --> 3 Recruiting --> Active, not recruiting
- | everolimus / Generic mfg.
Trial initiation date: S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (clinicaltrials.gov) - Feb 18, 2013
P3, N=3500, Recruiting, Sponsor: Southwest Oncology Group
Recruiting --> Active, not recruiting Initiation date: Sep 2012 --> Apr 2013
- ||| imatinib / Generic mfg., hydroxyurea / Generic mfg., everolimus / Generic mfg.
Trial completion, Combination therapy: Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG (clinicaltrials.gov) - Feb 18, 2013
P1, N=78, Completed, Sponsor: Annick Desjardins
Initiation date: Sep 2012 --> Apr 2013 Active, not recruiting --> Completed
- | everolimus / Generic mfg., fulvestrant / Generic mfg.
Enrollment closed, Metastases: BRE-43: Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure (clinicaltrials.gov) - Feb 17, 2013
P2, N=44, Active, not recruiting, Sponsor: Suleiman Massarweh
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | vistusertib (AZD2014) / AstraZeneca
New P2 trial, Metastases: ZEBRA: A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer (clinicaltrials.gov) - Feb 13, 2013
P2, N=122, Recruiting, Sponsor: Queen Mary University of London
- Farydak (panobinostat) / Secura Bio
Enrollment change: Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma (clinicaltrials.gov) - Feb 12, 2013
P1, N=11, Completed, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting N=36 --> 11
- Farydak (panobinostat) / Secura Bio
Trial completion: Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma (clinicaltrials.gov) - Feb 12, 2013
P1, N=11, Completed, Sponsor: City of Hope Medical Center
N=36 --> 11 Active, not recruiting --> Completed
- everolimus / Generic mfg.
Trial initiation date: Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 11, 2013
P1, N=40, Active, not recruiting, Sponsor: Bayside Health
Active, not recruiting --> Completed Initiation date: Mar 2008 --> Feb 2010
- everolimus / Generic mfg.
Enrollment change: Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 11, 2013
P1, N=40, Active, not recruiting, Sponsor: Bayside Health
Initiation date: Mar 2008 --> Feb 2010 N=24 --> 40
- everolimus / Generic mfg.
New P3 trial: Changes in the immune status (information on the status of the immune system)bei nierentransplantierten Patienten after switch to the immunosuppressive (suppression of immunological processes) therapy on the mTOR inhibitor everolimus (medication which prevent rejection following organ transplantation). An open-label (knowledge of the assigned treatment), non-randomized (no random allocation to treatment groups), single center (contacted in one study center) study. Ver (EUDRACT) - Feb 11, 2013
P3, N=40, Ongoing, Sponsor: Medizinische Universit
- everolimus / Generic mfg.
Enrollment closed: Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 11, 2013
P1, N=40, Active, not recruiting, Sponsor: Bayside Health
N=24 --> 40 Recruiting --> Active, not recruiting
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
New P4 trial: Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. (clinicaltrials.gov) - Feb 10, 2013
P4, N=31, Recruiting, Sponsor: Novartis Pharmaceuticals
- | everolimus / Generic mfg.
Enrollment open: Everolimus in Treating Cutaneous T-cell Lymphoma (clinicaltrials.gov) - Feb 10, 2013
P2, N=39, Recruiting, Sponsor: Boston Medical Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- everolimus / Generic mfg., erlotinib / Generic mfg.
Enrollment closed: Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Feb 10, 2013
P2, N=35, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Sutent (sunitinib) / Pfizer
New P2 trial: SUNRISES: Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer (clinicaltrials.gov) - Feb 4, 2013
P2, N=115, Recruiting, Sponsor: Associaci
- Fumena (vorolanib) / Tyrogenex, Betta Pharma
New P1/2 trial: VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Feb 4, 2013
P1/2, N=50, Recruiting, Sponsor: Washington University School of Medicine
- cisplatin / Generic mfg., everolimus / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Metastases: Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Feb 4, 2013
P1/2, N=55, Completed, Sponsor: Vanderbilt-Ingram Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed